Status:
COMPLETED
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Lead Sponsor:
Bayer
Conditions:
Magnetic Resonance Angiography
Peripheral Vascular Diseases
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdomi...
Eligibility Criteria
Inclusion
- Patients who are scheduled to undergo contrast-enhanced 3D-Magnetic Resonance Angiography
Exclusion
- Patients with an ankle brachial pressure index (ABPI) of 0.3 or less
- Patients with allergy to contrast media
- Patients with serious hepatic impairment
- Patients with serious renal impairment
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00652418
Start Date
July 1 2004
End Date
October 1 2004
Last Update
October 14 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hirosaki-shi, Aomori, Japan, 036-8563
2
Funai-gun, Kyoto, Japan, 629-0197
3
Hamamatsu, Shizuoka, Japan, 431-3192